How much does capmatinib cost per bottle?

Capmatinib (Capmatinib) is an oral small molecule mesenchymal-epithelial transition (MET) factor tyrosine kinase receptor inhibitor that blocks the binding of its ligand hepatocyte growth factor (HGF), which normally activates signaling pathways related to cell proliferation, movement and invasion. Capmatinib has potent activity against selected mutated forms of the MET receptor, including variants resulting from exon 14 skipping, and was found to inhibit cancer cell growth in several tissue culture and animal models of MET-dysregulated cancers.

Capmatinib was approved in the United States in 2020 for the treatment of adult patients with non-small cell lung cancer with documented mutations leading to MET exon 14 skipping, making it the first oncology drug approved for this indication. It is still evaluating other forms of cancer containing MET mutations. Capmatinib is available in 150 and 200 mg tablets under the brand name Tabrecta.

Capmatinib, an innovative drug, has not yet been launched in China, but it is already on sale in Hong Kong. In Hong Kong, a box containing 60 tablets of 200mg each costs more than 30,000 yuan, and the price will fluctuate with exchange rate changes.

At the same time, it is also available in overseas markets, such as the European version of capmatinib, which is 120 tablets per box and 200mg per tablet. The price has climbed to more than 50,000 yuan, which will also be affected by the exchange rate. Fortunately, overseas markets also offer more affordable generic drug options. The ingredients of these generic drugs are almost the same as those of the original drugs. For example, a drug produced in Laos with 56 tablets of 200 mg each costs only more than 3,000 yuan. Although the price may fluctuate with the exchange rate, its price has been significantly lower than that of the original drugs.